Skip to content
CancerIndex

Publication

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Maximilian Merz, Tomas Jelinek, Thomas Pabst, Raphael Teipel, Anca-Maria Albici, Bastian von Tresckow, Marcel Teichert, Uta Margareta Demel, Antonia Busse, Marie Christine Wesener, Tobias A W Holderried, Friederike Schmitz, Friedrich-Linus Rößiger, Fabian Müller, Michele Hoffmann, Friedrich Stölzel, Natalia Tovar, Ben-Niklas Baermann, Martin Stork, Alexandra Jungova, Jiri Minarik, Jakub Radocha, Ivan Spicka, Ludek Pour, Polona Novak, Klara Slajpah, Karla Rener, Ulrich Keller, Stephan Bohl, David Fandrei, Patrick Born, Vladan Vučinić, Nicolaus Kröger, Irene Strassl, Natalie Schub, Roman Hájek, Matjaž Sever, Carlos Fernández de Larrea, Nico Gagelmann

Blood cancer discoverySep 3, 2026PMID 42284467doi:10.1158/2643-3230.BCD-25-0461 PMC13539189Journal ArticleMulticenter StudypubmedProvenance
Source
PubMed
Retrieved
Sep 30, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260930-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

UNLABELLED: We explored single or consecutive chimeric antigen receptor (CAR) T and bispecific antibody (BsAb) treatment modalities as correlates of clinical outcomes, by complementary bias-correction analysis of a retrospective multicenter study of 640 patients with relapsed/refractory multiple…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.